RIG-I helicase-independent pathway in Sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer

Neoplasia

Volumn 12, Issue 11, 2010, Pages 906-914

  Kato, Tomonori ^a   Ueda, Yasuji ^a   Kinoh, Hiroaki ^a   Yoneyama, Yasuo ^a   Matsunaga, Akinao ^a   Komaru, Atsushi ^a   Harada, Yui ^a,b   Suzuki, Hiroyoshi ^a   Komiya, Akira ^a   Shibata, Satoko ^c   Hasegawa, Mamoru ^d   Hayashi, Hideki ^a   Ichikawa, Tomohiko ^a   Yonemitsu, Yoshikazu ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; GREEN FLUORESCENT PROTEIN; LIPOPOLYSACCHARIDE; RETINOIC ACID INDUCIBLE PROTEIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; IMMUNOSTIMULATION; LUNG METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SENDAI VIRUS;

EID: 78449258707     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10732     Document Type: Article

References (33)

1. Huggins C and Hodges CV (1941). Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1, 293-297.
2. Ichikawa T, Suzuki H, Ueda T, Komiya A, Imamoto T, and Kojima S (2005). Hormone treatment for prostate cancer: current issues and future directions. Cancer Chemother Pharmacol 56(suppl 1), 58-63.
3. Oh WK and Kantoff PW (1998). Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160, 1220-1229.
4. Borden LS Jr, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, Mohler R, and Torti FM (2006). Vinorelbine, doxorubicin, and prednisone in androgenindependent prostate cancer. Cancer 107, 1093-1100.
5. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebocontrolled trial. J Clin Oncol 21, 679-689.
6. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, and Boynton AL (1999). Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39, 54-59.
7. Rini BI and Small EJ (2003). The potential for prostate cancer immunotherapy. Crit Rev Oncol Hematol 46(suppl), S117-S125.
8. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, and Dalgleish AG (2004). Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94, 412-418.
9. Rosenberg SA, Yang JC, and Restifo NP (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med 10, 909-915.
10. Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata-Takeshita H, Inoue M, Zhu T, Hasegawa M, Moroi Y, et al. (2006). Induction of efficient antitumor immunity using dendritic cells activated by Sendai virus and its modulation of exogenous interferon-β gene. J Immunol 177, 3564-3576.
11. Yoneyama Y, Ueda Y, Akutsu Y, Matsunaga A, Shimada H, Kato T, Kubota-Akizawa M, Okano S, Shibata S, Sueishi K, et al. (2007). Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 355, 129-135.
12. Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery PK, et al. (2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18, 970-973.
13. Nagai Y (1999). Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 9, 83-99.
14. Markwell MA, Svennerholm L, and Paulson JC (1981). Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci USA 78, 5406-5410.
15. Moyer SA, Baker SC, and Lessard JL (1986). Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci USA 83, 5405-5409.
16. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, and Akira S (2005). IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6, 981-988.
17. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101-105.
18. Li HO, Zhu YF, Asakawa M, Kuma H, Hirata T, Ueda Y, Lee YS, Fukumura M, Iida A, Kato A, et al. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai viruswith efficient gene transfer and expression. J Virol 74, 6564-6569.
19. Doyle GM, Sharief Y, and Mohler JL (1992). Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. J Urol 147, 514-518.
20. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT, et al. (1995). Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Genes Chromosome Cancer 14, 112-119.
21. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, and Fujita T (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5, 730-737.
22. Grauer O, Wohlleben G, Seubert S, Weishaupt A, Kampgen E, and Gold R (2002). Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol 117, 351-362.
23. Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, and Moran TM (2004). TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 173, 6882-6889.
24. Hiraoka K, Yamamoto S, Otsuru S, Nakai S, Tamai K, Morishita R, Ogihara T, and Kaneda Y (2004). Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 173, 4297-4307.
25. Yoshikawa T, Okada N, Tsujino M, Gao JQ, Hayashi A, Tsutsumi Y, Mayumi T, Yamamoto A, and Nakagawa S (2006). Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol Pharm Bull 29, 100-104.
26. Trinite B, Voisine C, Yagita H, and Josien R (2000). A subset of cytolytic dendritic cells in rat. J Immunol 165, 4202-4208.
27. Park AY and Scott P (2001). IL-12: keeping cell-mediated immunity alive. Scand J Immunol 53, 529-532.
28. Yap G, Pesin M, and Sher A (2000). Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol 165, 628-631.
29. Brombacher F, Kastelein RA, and Alber G (2003). Novel IL-12 family members shed light on the orchestration of TH1 responses. Trends Immunol 24, 207-212.
30. Schmidt C, Brijs L, Cliquet P, and De Baetselier P (1998). Increased IL-12 P40 homodimer secretion by spleen cells during in vivo growth of the BW-19 T cell hybridoma accompanies suppression of natural immunity. Int J Cancer 77, 460-466.
31. Pirhonen J, Matikainen S, and Julkunen I (2002). Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169, 5673-5678.
32. Walter MJ, Kajiwara N, Karanja P, Castro M, and Holtzman MJ (2001). Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med 193, 339-351.
33. Komaru A, Ueda Y, Furuya A, Tanaka S, Yoshida K, Kato T, Kinoh H, Harada Y, Suzuki H, Inoue M, et al. (2009). Sustained and NK/CD4+ T-cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. J Immunol 183, 4211-4219.